Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Drugs in Development News & Deals for Idarubicin Hydrochloride

    Client Email Product

    Idarubicin Hydrochloride

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    REF. STANDARDS & IMPURITIES

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    15
    US DMFs Filed

    US DMFs Filed

    7
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    Listed Suppliers

    Listed Suppliers

    9
    API REF. PRICE (USD / KG)
    2,093,104

    API Market Place

    1
    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    13
    Europe

    Europe

    25
    Canada

    Canada

    1
    Australia

    Australia

    2
    South Africa

    South Africa

    3
    Uploaded Dossiers

    Uploaded Dossiers

    9
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    2
    EXCIPIENTS
    4
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    7
    REF STANDARD

    EDQM

    0

    USP

    1

    JP

    0

    Other Listed Suppliers

    1
    SERVICES

    0

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

    Details:

    The collaboration aims to evaluate Kura’s menin inhibitor, KO-539 (ziftomenib), in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-rearranged or NPM1-mutant acute leukemia.


    Lead Product(s): Ziftomenib,Fludarabine Phosphate,Idarubicin Hydrochloride

    Therapeutic Area: Oncology Product Name: KO-539

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Leukemia & Lymphoma Society

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration December 08, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    Transo Pharm Handels GmbH

    Access Virtual Booth

    Contact Supplier

    View Presentation

    fermion-oy-2024-05-13

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search